Short-Chain Fatty Acid Decreases the Expression of CEBPB to Inhibit miR-145-Mediated DUSP6 and Thus Further Suppresses Intestinal Inflammation

Abstract

Intestinal inflammation is a common disease which can further lead to inflammatory bowel disease and even intestinal cancer. The increasing focus has come to the role of shortchain fatty acid (SCFA) in various bowel diseases. Hence, this study was designed to explore the specific role of SCFA in intestinal inflammation. In vivo and in vitro models of intestinal inflammation were constructed by lipopolysaccharide (LPS) injection in mice and LPS treatment on intestinal epithelial cells. A possible regulatory mechanism involving SCFA, CCAAT enhancerbinding protein beta (CEBPB), microRNA-145 (miR-145), and dual-specificity phosphatase 6 (DUSP6) in intestinal inflammation was verified by ChIP assay and dual-luciferase reporter gene assay. To evaluate the effects of SCFA on LPS-treated intestinal epithelial cells, the expression of relevant genes and inflammatory factors (IL-6, TNF-α, and IL-1β) were determined. Last, the role of SCFA in vivo was explored through the scoring of disease activity index (DAI) and observation of colonic histology of LPS-treated mice. SCFA decreased the CEBPB expression in mouse colon tissues and small intestine epithelial cells induced by LPS. Furthermore, CEBPB could bind to the miR-145 promoter to inhibit its expression, thereby promoting the expression of DUSP6. In addition, SCFA improved the DAI, colonic histology, and the expression of

Small Extracellular Vesicles in Milk Cross the Blood-Brain Barrier in Murine Cerebral Cortex Endothelial Cells and Promote Dendritic Complexity in the Hippocampus and Brain Function in C57BL/6J Mice

“…RNA-seq data were analyzed as previously described (16). RNAseq data were validated for seven differentially expressed genes by using quantitative real-time PCR (qRT-PCR) with primers shown in Supplementary Table 1 (40)(41)(42)(43)(44)(45)(46)(47). Briefly, total RNA was reverse transcribed using the QuantiTec Reverse Transcription kit (Qiagen, Inc., Hilden, Germany) and qPCR was performed with SsoAdvanced Universal SYBR Green Supermix in a 10-µl reaction volume by following the manufacturer's instructions (Bio-Rad Laboratories, Inc., Hercules, CA, United States) using the following conditions: 94 • C for 3 min, followed by 40 cycles at 94 • C for 30 s, 60 • C for 30 s, and 72 • C for 30 s. The relative gene expression were calculated using 2 − Ct method with GAPDH as internal reference gene.…”

Relationship Between Short-chain Fatty Acids and Parkinson’s Disease: A Review from Pathology to Clinic

“…The latest research found intestinal inflammation could trigger gut-to-brain propagation of α-syn and amyloid protein β (Aβ) in a C/EBPβ/AEP-dependent manner [ 50 , 51 ]. Interestingly, SCFAs could inhibit the increased expression of C/EBPβ and thus further suppress intestinal inflammation [ 52 ]. Therefore, the role of SCFAs in regulating intestinal inflammation of PD and their effect on gut-brain transmission of α-syn should be a focus of research.…”

Health Benefits and Side Effects of Short-Chain Fatty Acids

“…Moreover, SCFAs transported by monocarboxylate transporter (MCT)-1 could suppress inflammatory responses in Caco-2 cells induced by TNF-α via decreasing IL-8 and IL-6 expression levels and inhibiting the activation of NF-κB, ERK, p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and spleen tyrosine kinase (Syk) [ 81 ]. Additionally, SCFAs prevented the development of intestinal inflammation via inhibiting dual-specificity phosphatase 6 (DUSP6) through the up-regulation of microRNA-145 (miR-145) by decreasing the CCAAT enhancer-binding protein beta (CEBPB) expression, and they also improved the disease activity index of LPS-treated mice [ 82 ].…”